Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05988008

A Study of CCX168 in Japanese and Caucasian Healthy Adult Males

Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis Clinical Trial

Official title:
A Phase I Clinical Study of CCX168 in Japanese and Caucasian Healthy Adult Males

Clinical Trial Summary

The objectives of the study will be to investigate the safety and pharmacokinetics of a single oral administration and a twice-daily multiple oral administration of CCX168 in Japanese healthy adult males; and to compare the pharmacokinetics of a single oral administration and a twice-daily multiple oral administration of CCX168 between Japanese and Caucasian healthy adult males.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

  • Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
  • Vasculitis
Clinical Trial Details
NCT number NCT05988008
Study type Interventional
Source Amgen
Contact
Status Completed
Phase Phase 1
Start date October 23, 2017
Completion date September 20, 2018
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06316076 - Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases Phase 1
Active, not recruiting NCT02198248 - Low-dose Glucocorticoid Vasculitis Induction Study Phase 4
Completed NCT06004960 - A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants Phase 1
Not yet recruiting NCT06350110 - Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) Phase 1/Phase 2
Withdrawn NCT01275287 - Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab Phase 2
Not yet recruiting NCT04871191 - Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis Phase 2
Recruiting NCT05732402 - An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases Phase 1/Phase 2
Not yet recruiting NCT06226662 - Study of NM8074 in Patients With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV) Phase 2
Terminated NCT02749292 - Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing Phase 4
Terminated NCT02294344 - The Clinical Efficacy of DFPP in Patients With AAGN N/A
Withdrawn NCT01275274 - Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens Phase 2
Completed NCT06004947 - A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications Phase 1
Recruiting NCT05969522 - Stratified Therapy on Pediatric AAGN Phase 4
Recruiting NCT03323476 - Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease Phase 3
Completed NCT05988021 - A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168 Phase 1
Terminated NCT01934504 - Defining Immune Tolerance in ANCA-associated Vasculitis (AAV) N/A
Recruiting NCT06056921 - Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease Phase 1
Not yet recruiting NCT02180126 - Differing Levels of Positive Anti-Neutrophil Cytoplasm Antibody (ANCA) Test and Their Correlation With Vasculitis or Malignancy or Chronic Inflammation N/A
Not yet recruiting NCT06379646 - An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease N/A
Recruiting NCT06294236 - Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM) Phase 1